Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Helius Medical Technologies (HSDT)
NASDAQ:HSDT
RESEARCH TOOLSreports
Holding HSDT?
Track your performance easily
Earnings Data
Report Date
Mar 13, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.94Last Year’s EPS
-$1.47Same Quarter Last Year
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 13, 2024
|% Change Since: 64.26%
|Next Earnings Date:Mar 13, 2025
Earnings Call Sentiment|Neutral
The earnings call presented several significant achievements, particularly in terms of partnerships, insurance reimbursements, and progress toward stroke authorization. However, it also highlighted a decrease in revenue year-over-year and a flat operating loss, suggesting financial challenges. Despite these lowlights, the positive developments in market access and potential revenue growth indicate a cautiously optimistic outlook.Company Guidance
During the second quarter of 2024, Helius Medical Technologies made significant progress in expanding access to its PoNS Therapy, particularly for veterans with MS. Key accomplishments include partnering with Lovell Government Services, securing approvals for inclusion in VA and GSA contracts, with pricing set at $23,843.72 for the PoNS device and $7,344.97 for the mouthpiece. Additionally, the therapy received its first third-party reimbursement of $23,900. PoNS was also approved for the Department of Defense’s DAPA contract, with device pricing at $23,724.50 and the mouthpiece at $7,308.25. These milestones are critical as Helius seeks CMS reimbursement, with HCPCS codes already assigned and final rates expected to be published soon. The company is also advancing its stroke authorization initiative, with studies underway in the U.S. and Canada, aiming for FDA submission in 2025. Financially, the company reported $182,000 in revenue for Q2 2024, a decrease from the previous year, but saw a 35% increase from Q1 2024 due to rising sales in the U.S. and Canada. Operating losses remained steady at $3.2 million, with a net loss of $1.6 million in the quarter.Partnership with Lovell Government Services
In April, Helius Medical partnered with Lovell Government Services to make PoNS Therapy accessible to MS patients treated at the VA and through other federal agencies, potentially benefiting 65,000 to 70,000 veterans in the U.S. living with MS.
Major Insurance Reimbursement
In May, Helius Medical received the first third-party reimbursement of $23,900 from a major insurance carrier for a PoNS device, marking a significant milestone in establishing market pricing.
Inclusion in Government Contracts
PoNS was approved for inclusion in the VA federal supply schedule and the General Services Administration Advantage contracts, as well as in Lovell's DAPA contract for the Department of Defense with established pricing.
Progress in Stroke Authorization
Significant progress was made towards stroke authorization in the U.S., with full enrollment in the registration program, aiming for FDA submission in 2025.
Revenue Increase Over Previous Quarter
Revenue for Q2 2024 was up 35% compared to Q1 2024 due to increased sales in both the U.S. and Canada.
---
HSDT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
HSDT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 13, 2024 | $0.55 | $0.56 | +1.82% |
| Aug 12, 2024 | $0.79 | $0.76 | -3.80% |
| May 13, 2024 | $1.69 | $1.56 | -7.69% |
| Mar 28, 2024 | $5.83 | $5.62 | -3.60% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Helius Medical Technologies (HSDT) report earnings?
Helius Medical Technologies (HSDT) is schdueled to report earning on Mar 13, 2025, TBA Not Confirmed.
What is Helius Medical Technologies (HSDT) earnings time?
Helius Medical Technologies (HSDT) earnings time is at Mar 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is HSDT EPS forecast?
HSDT EPS forecast for the fiscal quarter 2024 (Q4) is -$0.94.
---